Event Calendar

Upcoming Events
Q1 2017 Exelixis Inc. Financial Results Conference Call
Monday, May 1, 2017 5:00 p.m. ET
remind me days before the event

Exelixis, Inc. at Deutsche Bank’s Health Care Conference
Wednesday, May 3, 2017 11:20 a.m. ET
remind me days before the event

Enter your e-mail address 
Past Events
DateTitle
February 27, 2017 5:00 p.m. ET
Q4/FY 2016 Exelixis Inc. Financial Results Conference Call
Supporting Materials
Download Event Supporting Material  Exelixis Q4 2016 Financial Results
November 03, 2016 5:00 p.m. ET
Q3 2016 Exelixis Inc. Financial Results Conference Call
Supporting Materials
Download Event Supporting Material Exelixis Q3 2016 Financial Results
October 10, 2016 1:00 p.m. ET
Exelixis, Inc. at the European Society for Medical Oncology (ESMO) 2016 Congress
Description

Exelixis co-hosted an investor and media briefing at the ESMO 2016 Congress. During the 90 minute event, the company’s management team and invited guests reviewed data for cabozantinib presented at ESMO, including the results of the CABOSUN phase 2 randomized trial. The event also included a panel discussion with Drs. Toni K. Choueiri (Dana-Farber), Nizar Tannir (MD Anderson Cancer Center) and Sumanta Pal (City of Hope).

Supporting Materials
Download Event Supporting Material European Society for Medical Oncology (ESMO) 2016 Congress Presentation
Download Event Supporting Material Audio File
August 03, 2016 5:00 p.m. ET
Q2 2016 Exelixis Inc. Financial Results Conference Call
Supporting Materials
Download Event Supporting Material Exelixis Q2 2016 Financial Results
June 05, 2016 6:30 p.m. CT
Exelixis, Inc. 2016 ASCO Investor Briefing
Supporting Materials
Download Event Supporting Material ASCO Investor Briefing Presentation
May 04, 2016 5:00 p.m. ET
Q1 2016 Exelixis Inc. Financial Results Conference Call
Supporting Materials
Download Event Supporting Material Exelixis Q1 2016 Financial Results
April 25, 2016 4:00 p.m. ET
Exelixis, Inc. Conference Call to Discuss U.S. FDA Approval of CABOMETYX (Cabozantinib) Tablets
Supporting Materials
Download Event Supporting Material Exelixis U.S. FDA Approval of CABOMETYX (Cabozantinib) Tablets Presentation